Free Trial

AtriCure (ATRC) Competitors

AtriCure logo
$31.39 -0.81 (-2.52%)
Closing price 04:00 PM Eastern
Extended Trading
$31.35 -0.04 (-0.12%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ATRC vs. TFX, ITGR, ATEC, IART, SRDX, ANGO, OFIX, ARAY, RMTI, and RSLS

Should you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Teleflex (TFX), Integer (ITGR), Alphatec (ATEC), Integra LifeSciences (IART), Surmodics (SRDX), AngioDynamics (ANGO), Orthofix Medical (OFIX), Accuray (ARAY), Rockwell Medical (RMTI), and ReShape Lifesciences (RSLS). These companies are all part of the "health care equipment" industry.

AtriCure vs. Its Competitors

AtriCure (NASDAQ:ATRC) and Teleflex (NYSE:TFX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

99.1% of AtriCure shares are owned by institutional investors. Comparatively, 95.6% of Teleflex shares are owned by institutional investors. 3.5% of AtriCure shares are owned by insiders. Comparatively, 1.4% of Teleflex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

AtriCure presently has a consensus target price of $50.67, indicating a potential upside of 61.41%. Teleflex has a consensus target price of $164.63, indicating a potential upside of 35.61%. Given AtriCure's stronger consensus rating and higher possible upside, equities analysts clearly believe AtriCure is more favorable than Teleflex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AtriCure
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00
Teleflex
1 Sell rating(s)
8 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.09

Teleflex has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtriCure$465.31M3.34-$44.70M-$0.81-38.75
Teleflex$3.05B1.76$69.68M$3.1738.30

AtriCure has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Teleflex has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Teleflex has a net margin of 4.96% compared to AtriCure's net margin of -7.95%. Teleflex's return on equity of 14.73% beat AtriCure's return on equity.

Company Net Margins Return on Equity Return on Assets
AtriCure-7.95% -5.68% -4.34%
Teleflex 4.96%14.73%8.79%

In the previous week, Teleflex had 16 more articles in the media than AtriCure. MarketBeat recorded 19 mentions for Teleflex and 3 mentions for AtriCure. AtriCure's average media sentiment score of 1.44 beat Teleflex's score of 0.36 indicating that AtriCure is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AtriCure
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Teleflex
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

AtriCure and Teleflex tied by winning 8 of the 16 factors compared between the two stocks.

Get AtriCure News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATRC vs. The Competition

MetricAtriCureMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$1.59B$10.49B$5.54B$8.87B
Dividend YieldN/A2.09%5.39%4.10%
P/E Ratio-38.7516.6626.1419.88
Price / Sales3.3429.93414.67113.66
Price / CashN/A22.7836.1356.90
Price / Book3.323.648.055.38
Net Income-$44.70M$233.36M$3.15B$248.50M
7 Day Performance-2.73%1.41%1.85%2.97%
1 Month Performance-7.68%3.40%4.81%6.02%
1 Year Performance40.20%-11.84%34.86%20.39%

AtriCure Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATRC
AtriCure
3.5524 of 5 stars
$31.39
-2.5%
$50.67
+61.4%
+43.1%$1.59B$465.31M-38.751,300Positive News
TFX
Teleflex
4.6847 of 5 stars
$118.12
-0.2%
$164.63
+39.4%
-42.5%$5.23B$3.05B37.2614,100News Coverage
Analyst Downgrade
ITGR
Integer
3.5811 of 5 stars
$119.06
+1.1%
$145.00
+21.8%
+5.5%$4.11B$1.72B56.4311,000
ATEC
Alphatec
4.2483 of 5 stars
$10.86
-0.7%
$17.89
+64.7%
+9.5%$1.60B$611.56M-9.44700
IART
Integra LifeSciences
4.0974 of 5 stars
$11.62
+0.2%
$18.63
+60.3%
-54.3%$901.46M$1.61B-30.584,396
SRDX
Surmodics
4.2818 of 5 stars
$29.00
flat
$43.00
+48.3%
-30.1%$414.68M$126.08M-20.86450News Coverage
Analyst Revision
ANGO
AngioDynamics
3.9826 of 5 stars
$9.99
-0.3%
$14.00
+40.1%
+66.4%$406.88M$303.91M-9.89760Positive News
OFIX
Orthofix Medical
3.0822 of 5 stars
$10.80
+4.4%
$21.50
+99.1%
-13.2%$404.93M$799.49M-2.931,616
ARAY
Accuray
3.6399 of 5 stars
$1.25
+2.5%
N/A-22.7%$125.68M$446.55M-25.001,040
RMTI
Rockwell Medical
4.2975 of 5 stars
$0.87
-2.2%
$4.00
+359.5%
-50.2%$30.42M$101.49M-43.53300News Coverage
Gap Down
RSLS
ReShape Lifesciences
0.1503 of 5 stars
$2.56
+0.4%
N/A-99.2%$6.08M$8.01M-0.0150

Related Companies and Tools


This page (NASDAQ:ATRC) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners